• Diana Hernández-Romero, José María García-Salas, Angel López-Cuenca, Patricio Pérez-Berbel, Carmen Puche, Teresa Casas, Esteban Orenes-Piñero, Sergio Manzano-Fernández, Mariano Valdés, and Francisco Marín.
• Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, 30120 Murcia, Spain. dianahr@um.es
• ScientificWorldJournal. 2012 Jan 1;2012:578616.

UnlabelledHigh-sensitivity TnT (hsTnT) has been proposed to improve the diagnosis and stratification in acute coronary syndromes. Copeptin has been proposed for a rapid and accurate rule out of acute myocardial infarction, but some doubts exist about its use out of the first hours from admission. Abnormalities of serum hsTnT and copeptin levels in non-STEACS and negative TnT, could have prognostic implications.MethodsWe included 122 non-STEACS patients without raised TnT, 33 disease controls and 43 healthy controls. We measured hsTnT and copeptin levels. Clinical follow-up at 12 months was performed for adverse endpoints.ResultsNon-STEACS patients had raised hsTnT compared with both control groups (P = 0.036 and P < 0.001). Copeptin levels were higher in non-STEACS patients than healthy controls (P = 0.021), without differences with disease controls. Raised levels of hs-TnT presented prognostic implications [HR 3.29 (95%CI: 1.33-7.49), P = 0.010]. hs-TnT could be used for invasive approach decision, as it shows prognostic relevance in conservative approach-patients whereas remains unrelevant for catheterized-patients. Copeptin levels were not associated with adverse events.ConclusionhsTnT levels increased in non-STEACS, were predictive of adverse events and could be important for recommending an invasive management. We cannot confirm a predictive role of copeptin out of the first hours from admission.

18 keywords...

hide…